Reata Pharmaceuticals, Inc. Class A Common Stock
RETA
RETA was delisted on the 25th of September, 2023.
157 hedge funds and large institutions have $1.4B invested in Reata Pharmaceuticals, Inc. Class A Common Stock in 2019 Q1 according to their latest regulatory filings, with 38 funds opening new positions, 48 increasing their positions, 47 reducing their positions, and 12 closing their positions.
217% more first-time investments, than exits
New positions opened: 38 | Existing positions closed: 12
56% more capital invested
Capital invested by funds: $895M → $1.4B (+$505M)
30% more call options, than puts
Call options by funds: $12.2M | Put options by funds: $9.37M
20% more funds holding
Funds holding: 131 → 157 (+26)
2% more repeat investments, than reductions
Existing positions increased: 48 | Existing positions reduced: 47
0% more funds holding in top 10
Funds holding in top 10: 5 → 5 (0)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Vanguard Group
Malvern,
Pennsylvania
|
+$35.4M |
| 2 |
Millennium Management
New York
|
+$29.3M |
| 3 |
TCIM
TIAA CREF Investment Management
New York
|
+$13.8M |
| 4 |
AAMU
Amundi Asset Management US
Boston,
Massachusetts
|
+$11.1M |
| 5 |
RHJA
Rice Hall James & Associates
San Diego,
California
|
+$9.62M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
-$12.1M |
| 2 |
SFM
Sphera Funds Management
Tel Aviv,
Israel
|
-$11.6M |
| 3 |
EMFAT
Emerald Mutual Fund Advisers Trust
Leola,
Pennsylvania
|
-$10.5M |
| 4 |
BlackRock
New York
|
-$8.41M |
| 5 |
Deutsche Bank
Frankfurt Am Main Ge,
Germany
|
-$8.1M |
RETA Hedge Fund Activity: Q1 2019 in Review
157 of the 4,621 institutional investors tracked by Wall St. Rank reported a position in Reata Pharmaceuticals, Inc. Class A Common Stock (RETA) for Q1 2019, worth a combined $1.4B — up 56% from $895M a quarter earlier.
Buyers outnumbered sellers: 38 funds opened new RETA positions and 12 closed out — a net gain of 26 holders — while 48 added to existing stakes and 47 trimmed.
The largest buyer was Vanguard Group, adding an estimated $35.4M. The largest seller was Fidelity Investments, cutting an estimated $12.1M.
- 157 institutional investors held Reata Pharmaceuticals, Inc. Class A Common Stock (RETA) as of Q1 2019, up from 131 in Q4 2018.
- Funds reported $1.4B of Reata Pharmaceuticals, Inc. Class A Common Stock stock for Q1 2019, up 56% quarter-over-quarter.
- 38 funds opened new Reata Pharmaceuticals, Inc. Class A Common Stock positions in Q1 2019 and 12 closed out, a net change of +26 holders.
- The largest Reata Pharmaceuticals, Inc. Class A Common Stock buyer in Q1 2019 was Vanguard Group, an estimated $35.4M added.
- The largest Reata Pharmaceuticals, Inc. Class A Common Stock seller in Q1 2019 was Fidelity Investments, an estimated $12.1M sold.
Based on aggregated 13F filings for Q1 2019.